CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pfizer Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pfizer Inc
66 HUDSON BOULEVARD EAST
Phone: (212) 733-2323p:212 733-2323 NEW YORK, NY  10001-2192  United States Ticker: PFEPFE
Business Summary
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/29/202412/31/2023YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer AlbertBourla 62 1/1/2020 1/1/2014
Executive Vice President, Chief Financial Officer David M.Denton 58 5/2/2022 5/2/2022
Executive Vice President, Chief People Experience Officer PayalSahni 49 1/1/2022 1/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
PFIZER (M) SDN BHD
PFIZER CORPORATION HK LTD
PFIZER GLOBAL SUPPLY JAPAN INC
168 additional Subsidiary records available in full report.

Business Names
Business Name
356 Royalty Inc.
Agouron Pharmaceuticals, LLC
AH Robins LLC
319 additional Business Names available in full report.

General Information
Number of Employees: 88,000 (As of 12/31/2023)
Outstanding Shares: 5,666,990,035 (As of 10/30/2024)
Shareholders: 123,387
Stock Exchange: NYSE
Federal Tax Id: 135315170
Fax Number: (302) 655-5049
Email Address: learnmore@sg2.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024